Multiple myeloma is a clonal plasma cell disorder that commonly affect bones, leading to characteristic bone findings on imaging studies. Here, we present the case of male patient in his late-forties who presented with back pain and was found have lytic lesions skull pelvis X-ray. Further workup confirmed diagnosis started chemotherapy denosumab. This highlights importance early recognition stu...

This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for treatment of relapsed and refractory multiple myeloma. Based on results phase 2 3 trials, these are proposed patients with disease who have received one previous line therapy, myeloma two or more lines therapy. These integrate issue drug access in both low-income middle-income countries h...

DEPTOR is a 48 kDa protein that binds to mTOR and inhibits this kinase in TORC1 and TORC2 complexes. Overexpression of DEPTOR specifically occurs in a model of multiple myeloma. Its silencing in multiple myeloma cells is sufficient to induce cytotoxicity, suggesting that DEPTOR is a potential therapeutic target. mTORC1 paralysis protects multiple myeloma cells against DEPTOR silencing, implicat...

PURPOSE PD-1/PD-L1 signaling promotes tumor growth while inhibiting effector cell-mediated antitumor immune responses. Here, we assessed the impact of single and dual blockade of PD-1/PD-L1, alone or in combination with lenalidomide, on accessory and immune cell function as well as multiple myeloma cell growth in the bone marrow (BM) milieu. EXPERIMENTAL DESIGN Surface expression of PD-1 on i...

PURPOSE Doxorubicin has shown efficacy especially in combination treatment for the treatment of multiple myeloma; however, its side effects limit its use. INNO-206 is an albumin-binding prodrug of doxorubicin, which is released from albumin under acidic conditions. Because INNO-206 has not been previously evaluated in any hematologic malignancy, we determined its anti-multiple myeloma effects. ...